Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer

Journal of Clinical Oncology

Volumn 15, Issue 4, 1997, Pages 1354-1366

  Ahlert, T ^a   Sauerbrei, W ^a   Bastert, G ^a   Ruhland, S ^a   Bartik, B ^a   Simiantonaki, N ^a   Schumacher, J ^a   Hacker B ^a   Schumacher, M ^a   Schirrmacher, V ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CANCER VACCINE; CIMETIDINE; CYANOCOBALAMIN; CYCLOPHOSPHAMIDE; CYTOKINE; EPIRUBICIN; INDOMETACIN; PYRIDOXINE; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT INTERLEUKIN 2; RETINOL; THIAMINE; TUMOR CELL VACCINE; VITAMIN;

ADULT; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELL COUNT; CELL VIABILITY; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG EFFICACY; DRUG QUALITY; FEMALE; GAMMA RADIATION; GOOD MANUFACTURING PRACTICE; HUMAN; HUMAN CELL; IMMUNOGENICITY; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; NEWCASTLE DISEASE PARAMYXOVIRUS; ORAL DRUG ADMINISTRATION; OVARY CANCER; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; VACCINE PRODUCTION;

EID: 0030951625     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.4.1354     Document Type: Article

References (68)

1. Pardoll D: New strategies for active immunotherapy with genetically engineered tumor cells. Curr Opin Immunol 4:619-623, 1992
2. Sobol RE, Fakhrai H, Gjerset R: Active tumor immunotherapy with transduced fibroblasts. Protocols Am Assoc Cancer Res 33:495-502, 1992
3. Tsai J, Gansbacher B, Tait L, et al: Induction of antitumor immunity by interleukin-2 gene-transduced mouse mammary tumor cells versus transduced mammary stromal fibroblasts. J Natl Cancer Inst 85:546-502, 1993
4. Schlom J, Kantor J, Abrams S, et al: Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer. Breast Cancer Res Treat 38:27-39, 1996
5. Klein G, Sjögren HO, Klein E, et al: Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res 20:1561-1572, 1960
6. Ioannides CG, Platsoucas CD, Patenia R, et al: T-cell functions in ovarian cancer patients treated with viral oncolysates: I. Increased helper activity to immunoglobulins production. Anticancer Res 10:645-654, 1990
7. Schild HJ, Hoegen von P, Schirrmacher V: Modification of tumor cells by a low dose of Newcastle disease virus. II. Augmented tumor-specific T cell responses as a result of CD4+ and CDS+ immune T cell cooperation. Cancer Immunol Immunother 28:22-28, 1989
8. Schirrmacher V, Griesbach A, Zangemeister-Wittke U: γ-Irradiated viable tumor cells as whole-cell vaccines can stimulate in situ syngeneic antitumor cytotoxic T lymphocytes and delayed-type hypersensitivity reactivity whereas tumor cell lysates elicit only delayed-type hypersensitivity reactivity. Vaccine Res 3:31-48, 1994
9. Schirrmacher V, Schild H-J, Gückel B, et al: Tumor specific CTL response requiring interactions of four different cell types and dual recognition of MHC class I and class II restricted tumor antigens. Immunol Cell Biol 71:311-326, 1992
10. Schirrmacher V: Tumor vaccine design: Concepts, mechanisms and efficacy testing. Int Arch Allergy Immunol 108:340-344, 1995
11. Kobayashi H: Viral xenogenisation of intact tumor cells. Adv Cancer Res 30:279-299, 1979
12. Hoegen von P, Heicappell R, Griesbach A, et al: Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. III Postoperative activation of tumor specific CTLP from mice with metastases requires stimulation with the specific antigen plus additional signals. Invasion Metastasis 9:117-133, 1989
13. Hoegen von P, Schirrmacher V: Activation of tumor-specific CTLP to a cytolytic stage requires additional signals. Cytotoxic T Cells 532:468-471, 1988
14. Hellström I, Hellström K-E: Tumor immunology: An overview. Specific immunotherapy of cancer with vaccines. Ann NY Acad Sci 690:24-33, 1993
15. Leach DR, Krummel MF, Allison JP: Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734-1736, 1996
16. Schirrmacher V: Immunity and metastasis: In situ activation of protective T cells by virus modified cancer vaccines. Cancer Surv 13:129-153, 1992
17. Colombo M, Forni G: Cytokine gene transfer in tumor inhibition and tumor therapy: Where are we now? Immunol Today 15:48-51, 1994
18. Restifo NP, Spiess PJ, Karp SE, et al: A non-immunogenic sarcoma transduced with the cDNA for interferon gamma elicits CDS+ T cells against the wild-type tumor: Correlation with antigen presentation capability. J Exp Med 175:1423-1431, 1992
19. Ahlert T, Kaufmann M, Bastert G, et al: Active specific immunotherapy (ASI) with virally modified autologous tumor cells in breast and ovarian cancer: Factors influencing immunological vaccination success. J Cancer Res Clin Oncol 116:80, 1990 (suppl, abstr)
20. Peters LC, Hanna MG: Active-specific immunotherapy of established micrometastasis: Effect of cryopreservation procedures on tumor cell immunogenicity in guinea pigs. J Natl Cancer Inst 64:1521-1525, 1980
21. Sedlacek HH, Weise M, Lemmer A, et al: Immunotherapy of spontaneous mammary tumors in mongrel dogs with autologous tumor cells and neuraminidase. Cancer Immunol Immunother 6:47-58, 1979
22. Heicappell R, Schirrmacher V, Hoegen von P, et al: Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. I. Parameters for optimal therapeutic effects. Int J Cancer 37:569-577, 1986
23. Schirrmacher V, Heicappell R: Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. II. Establishment of specific anti-tumor immunity. Clin Exp Metastasis 5:147-156, 1987
24. Schirrmacher V, Ahlert T, Heicappell R, et al: Successful application of non-oncogenic viruses for antimetastatic cancer immunotherapy. Cancer Res 5:19-49, 1986
25. Ertel C, Millar NS, Emmerson PT, et al: Viral hemagglutinin augments peptide-specific cytotoxic T cell responses. Eur J Immunol 23:2592-2596, 1993
26. Kaido T, Maury C, Schirrmacher V, et al: Successful immunotherapy of the highly metastatic murine ESb lymphoma with sensitized CDS+ T cells and IFN-alpha/beta. Int J Cancer 57:538-543, 1994
27. Lucia G, Proietti E, Giampaolo G, et al: Isolation and characterization of a metastatic Eb-like tumor variant highly responsive to interleukin (IL)-2 and to combination cytokine therapy with I1-2/IL-1 and IL-1 beta/interferon-alpha/beta. Invasion Metastasis 13:147-162, 1993
28. Schirrmacher V, Hoegen von P: Importance of tumor cell membrane integrity and viability for cytotoxic T lymphocyte activation by cancer vaccines. Vaccine Res 2:183-196, 1993
29. Ahlert T: Tumor cell vaccination and I1-2-therapy. Hybridoma 12:549-552, 1993
30. Ahlert T and Schirrmacher V: Isolation of a human melanoma adapted Newcastle disease virus mutant with highly selective replication patterns. Cancer Res 50: 5962-5968, 1990
31. Bohle W, Schlag P, Liebrich W, et al: Postoperative active, specific immunization in colorectal cancer patients with virus-modified autologous tumor cell vaccine. Cancer 66:1517-1523, 1990
32. Lehner B, Schlag P, Liebrich W, et al: Postoperative active specific immunization in curatively resected colorectal cancer patients with virus-modified autologous tumor cell vaccine. Cancer Immunol Immunother 32:173-179, 1990
33. Liebrich W, Schlag P, Manasterski M, et al: In vitro and clinical characterisation of a Newcastle disease virus-modified autologous tumor cell vaccine for treatment of colorectal cancer patients. Eur J Cancer 27:703-710, 1991
34. Schirrmacher V, Hoegen von P, Schlag P, Liebrich W, et al: Active specific immunotherapy with autologous tumor cell vaccines modified by Newcastle disease virus: Experimental and clinical studies, in Schirrmacher V, Schwartz-Albiez R (eds): Cancer Metastasis. Berlin, Germany, Springer-Verlag, 1989, pp 157-170
35. Schlag P, Manasterski M, Gerneth T, et al: Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. Cancer Immunol Immunother 35:325-330, 1992
36. Thiele R, Pomer S, Stähler G, et al: Comparison of active specific immunotherapy with and without local application of I12 in renal cancer patients. J Cancer Res Clin Oncol 116:80, 1990 (abstr)
37. Ehrke MJ, Mihich E, Berd D, et al: Effects of anticancer drugs on the immune system in humans. Oncology 16:230-253, 1989
38. Khan MM, Sansoni P, Englemen EG, et al: Pharmacologic effects of autacoids on subsets of T-cells: Regulation of expression/function of histamine-2 receptors by a subset of suppressor cells. J Clin Invest 75:1578-1583, 1985
39. Murray JL, Hersh EM: In vitro inhibition of interleukin-2 production by peripheral blood lymphocytes from stage III melanoma patients by prostaglandin E2: Enhancement of lymphocyte proliferation by exogenous interleukin-2 plus indomethacin. J Biol Resp Modif 5:12-19, 1985
40. Sahasrabudhe DM, McCune CS, ODonnel RW, et al: Inhibition of suppressor T-lymphocytes by cimetidine. J Immunol 138:2760-2763, 1987
41. Wanebo HJ, Riley T, Katz D, et al: Indomethacin sensitive suppressor-cell activity in head and neck cancer patients; The role of the adherent mononuclear cell. Cancer 61:462-474, 1988
42. Friese K, Wesch D, Gallati H, et al: Untersuchung zur Zytokin-Produktion bei gynäkologischen Karzinomen. Geburtshilfe Frauenheilkd 51:1138-1141, 1991
43. Sedman PC, Ramsden CW, Brennan TG, et al: Effects of low dose perioperative Interferon on the surgically induced suppression of antitumor immune responses. Br J Surg 75:979-981, 1988
44. Arroyo PJ, Bash JA, Wallack MC: Active specific immunotherapy with vaccinia colon oncolysate enhances the immunomodulatory and antitumor effects of interleukin-2 and interferon alpha in a murine hepatic metastasis model. Cancer Immunol Immunother 31:305-311, 1990
45. Bubenik J: Local and regional immunotherapy of cancer with interleukin-2. Cancer Res Clin Oncol 116:1-7, 1990
46. Cortesina G, Stefani A, Giovarelli M, et al: Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of interleukin-2 injected perilymphatically. Cancer 62:2482-2485, 1988
47. Hoover HCJ, Surdyke M, Dangel RB, et al: Delayed cutaneous hypersensitivity to autologous tumor cells in colorectal cancer patients immunized with an autologous tumor cell: Bacillus Calmette-Guérin vaccine. Cancer Res 44:1671-1676, 1984
48. Stoeck M, Marland-Noske C, Manasterski M, et al: In vitro expansion and analysis of T lymphocyte microcultures obtained from the vaccination sites of cancer patients undergoing active specific immunization with autologous Newcastle-disease-virus modified tumor cells. Cancer Immunol Immunother 37:240-244, 1993
49. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481,1958
50. Cox DR: Regression models and life tables (with discussion). J R Stat Soc B 74:187-220, 1972
51. Altman DG (eds): Practical Statistics for Medical Research. London, United Kingdom, Chapman & Hall, 1991
52. Brummer T, Kaul S, Bastert G, et al: Immunoscintigraphy of human mammary carcinoma xenographs using monoclonal antibodies to 12H12 and BM2 labeled with 99mTc and radio-iodine. Cancer Res 54:4162-4168, 1994
53. Cassel WA, Murray DR, Phillips HS: A phase II study on the postsurgical management of stage II malignant melanoma with a Newcastle disease virus oncolysate. Cancer 52:856-860, 1983
54. Hersey P, Edwards A, Coates A, et al: Evidence that treatment with vaccinia melanoma cell lysates (VMCL) may improve survival of patients with stage II melanoma. Cancer Immunol Immunother 25:257-265, 1987
55. Cassel WA, Murray DR: A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate. Med Oncol Tumor Pharmacother 9:169-171, 1992
56. Tallberg T, Kalima T, Halttunen P, et al: Postoperative active specific immunotherapy with supportive measures in patients suffering from recurrent metastasized melanoma case reports of six patients. J Surg Oncol 33:115-119, 1986
57. Tallberg T, Tykka H, Mahlberg K, et al: Active specific immunotherapy with supportive measure in the treatment of palliatively nephrectomized renal adenocarcinoma patients. Eur Urol 11:233-243, 1985
58. Mitchell MS, Harel W, Kempf RA, et al: Active-specific immunotherapy for melanoma. J Clin Oncol 8:856-869, 1990
59. Sinkovics JG: Viral oncolysates as human tumor vaccines. Im Rev Immunol 7:259-287, 1991
60. Ahlert T, Gremm B, Kohler S, et al: Klinische Erfahrungen mit aktiv-spezifischer Immuntherapie in frühen und späten Stadien gynäkologischer Malignome, in Basten G, Wallwiener D, Manth SM (eds): Immuntherapie in der gynäkologischen Onkologie, Realität oder Fiktion. Heidelberg, Germany, Springer Verlag, 1994, pp 1-18
61. Ahlert T, Striffler H, Bastert G, et al: Aktueller Stand gynäkologischer Studien zur aktiven spezifischen Immuntherapie mit virus-modifizierten autologen Tumorzellen. Aktuelle Onkol 60:196-204, 1991
62. Valitutti S, Müller S, Cella M, et al: Serial triggering of many T cell receptors by a few peptide-MHC complexes. Nature 375:148-151, 1995
63. Berd D, Maguire HC, McCue P, et al: Treatment of metastatic melanoma with an autologous tumor cell vaccine: Clinical and immunologic results in 64 patients. J Clin Oncol 8:1858-1867, 1990
64. Harris J, Ryan L, Adams G, et al: Survival and relapse in adjuvant autologous tumor vaccine therapy for dukes B and C colon cancer. Proc Am Soc Clin Oncol 13:294, 1994 (abstr)
65. Hoover HC, Brandhorst JS, Peters LC, et al: Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol 11:390-399, 1993
66. McCune CS, O'Donnell RW, Marquis DM, et al: Renal cell carcinoma treated by vaccines for active specific immunotherapy: Correlation of survival with skin testing by autologous tumor cells. Cancer Immunol Immunother 32:62-66, 1990
67. Wallack MK, Sivanadham M, Balch CM, et al: A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate - Active specific immunotherapy for patients with stage II melanoma. Cancer 75:34-42, 1995
68. Ockert D, Schirrmacher V, Beck N, et al: Newcastle disease virus infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. Clin Cancer Res 2:21-28, 1996